Berlin Heals Publishes Significant Two-Year Study Outcomes
The study highlights lasting improvements in heart failure symptoms and overall function following prolonged C-MIC therapy.
Overview of the Published Study
Berlin Heals, renowned for its innovations in bioelectric medicine for heart failure treatments, recently published a notable study titled "Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot study" in the respected journal ESC Heart Failure. This comprehensive research focuses on the long-term results of patients who participated in the initial pilot trial involving the Cardiac Microcurrent Implantable Device (C-MIC).
Long-Term Benefits of C-MIC Therapy
The study explores the follow-up results from seven patients with chronic heart failure (NYHA Class III, mean LVEF 31.7%) who received the C-MIC treatment. Key parameters assessed included mortality, hospitalization rates, adverse events related to the device, and the overall functional status of these patients.
Key Findings from the Study
The results revealed several promising outcomes, illustrating the efficacy and safety of the C-MIC therapy:
- No adverse events associated with the device occurred over the study's two-year span.
- LVEF enhancements of +11.6% at 6 months were effectively maintained at +12.6% two years after ceasing active therapy.
- 6-minute walk distance (6MWD) improved dramatically by over 200 meters at the six-month mark and remained nearly 191 meters above baseline two years later.
- Participants showed sustained improvement in both NYHA functional class and SF-36 quality-of-life scores.
- Only one individual required reactivation of the C-MIC device.
Insights from the Researchers
Prof. Dragana Kosevic, who led the study, expressed optimism regarding the results: "These findings provide significant insights into the long-term advantages of C-MIC therapy. The improvements in cardiac function and patient well-being appear to persist even after the device's deactivation, suggesting a potential disease-modifying effect."
Company Perspective on the Results
Berlin Heals CEO John Brumfield commented on the study's publication: "It strengthens our belief in microcurrent therapy as a revolutionary treatment option for heart failure. The two-year outcomes validate both the safety and enduring effects of C-MIC, laying the groundwork for more extensive clinical trials to follow."
Future Clinical Development Plans
The company is committed to expanding its clinical development initiatives, with the multicenter C-MIC III trial already underway across several European nations, aiming to further assess the efficacy of this innovative therapy.
Frequently Asked Questions
What is C-MIC therapy?
C-MIC therapy utilizes a specialized device aimed at improving cardiac function in patients with chronic heart failure.
What were the main findings of the two-year study?
The study found sustained improvements in cardiac function and quality of life, with no adverse events related to the device.
Who conducted the study and where was it published?
The study was conducted by researchers at Berlin Heals and published in the journal ESC Heart Failure.
What implications do these results have for heart failure treatment?
The findings suggest that C-MIC therapy may have long-term benefits and could potentially modify the progression of heart disease.
Are there ongoing trials related to C-MIC therapy?
Yes, Berlin Heals is currently conducting the multicenter C-MIC III trial to further evaluate the therapy's efficacy.
